Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) were up 1.9% on Monday . The company traded as high as $11.25 and last traded at $11.06, with a volume of 165,392 shares traded. The stock had previously closed at $10.85.

A number of analysts have recently weighed in on ESPR shares. WallachBeth Capital downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price target for the company. in a report on Tuesday, July 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target (down previously from $77.00) on shares of Esperion Therapeutics in a report on Wednesday, June 29th. Zacks Investment Research raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. JPMorgan Chase & Co. set a $15.00 price target on shares of Esperion Therapeutics and gave the stock a “hold” rating in a report on Friday, August 5th. Finally, Vetr raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 price target for the company in a report on Monday, July 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $24.40.

The firm’s market capitalization is $264.06 million. The stock’s 50-day moving average is $10.95 and its 200 day moving average is $14.86.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.16. During the same quarter in the previous year, the company posted ($0.55) earnings per share. On average, equities analysts predict that Esperion Therapeutics Inc. will post ($3.36) earnings per share for the current year.

In other Esperion Therapeutics news, Director Mark E. Mcgovern bought 5,000 shares of Esperion Therapeutics stock in a transaction dated Wednesday, July 6th. The stock was purchased at an average price of $10.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the director now directly owns 600 shares of the company’s stock, valued at $6,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.